Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | USP5 | P45974 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993673 | 0.81 | CNR2 (0.73) | CNR1CNR2ALDH1A1POLBMEN1 | |
| SCHEMBL4049757 | 0.81 | ALDH1A1 (0.47) | CNR1CNR2LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1999477 | 0.80 | CNR1 (0.51) | CNR1CNR2LMNASMN1; SMN2RORC | |
| SCHEMBL2000823 | 0.77 | CNR1 (0.48) | CNR1CNR2LMNASMN1; SMN2HPGD | |
| SCHEMBL2008950 | 0.75 | RORC (0.53) | CNR1CNR2LMNASMN1; SMN2HPGD | |
| SCHEMBL12567617 | 0.75 | CNR1 (0.46) | CNR1CNR2RORCGNRHR | |
| SCHEMBL2002470 | 0.74 | MAPT (0.45) | CNR2LMNASMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL1999752 | 0.74 | MAPT (0.45) | CNR1CNR2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2000042 | 0.72 | TSHR (0.47) | SMN1; SMN2HPGDALDH1A1KMT2A | |
| SCHEMBL13907098 | 0.71 | CPT2 (0.47) | CNR1CNR2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | CNR1 1/4885CNR2 2/4885LMNA 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.